Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
boston blog main
boston top stories
7
×
boulder/denver blog main
boulder/denver top stories
cancer
7
×
detroit blog main
detroit top stories
indiana blog main
indiana top stories
investing
7
×
life sciences
national
national blog main
national top stories
new york blog main
new york top stories
raleigh-durham blog main
raleigh-durham top stories
san diego blog main
7
×
san diego top stories
7
×
san francisco blog main
san francisco top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
pfizer
startups
cancer immunotherapy
clinical trials
deals
eli lilly
fda
alexion pharmaceuticals
bristol-myers squibb
roche
takeda pharmaceutical
What
bio
7
×
roundup
drug
alzheimer’s
companies
drugs
fda
growing
new
pharmaceutical
plan
prices
typically
advantages
ahead
alliance
annual
approved
asco
assessed
attention
bails
bar
biotech
brand
branded
bridgebio
brings
bristol
buy
calls
capital
car
changing
choices
color
commissioner
communities
conference
consumers
Language
unset
Current search:
investing
×
bio
×
" san diego blog main "
×
" boston top stories "
×
cancer
×
" san diego top stories "
×
@xconomy.com
3 years ago
Bio Roundup: CRISPR Kudos, Bristol Myers’s Buy, RNAi Alliance & More
@xconomy.com
4 years ago
Bio Roundup: Ichnos Emerges, Beyond CAR-T, BridgeBio Bails & More
@xconomy.com
4 years ago
Bio Roundup: MedCo’s Pricing Plan, Vertex’s Gamble, uBiome Undone
@xconomy.com
5 years ago
Bio Roundup: Generic Drugs Graft, ASCO Ahead, ElevateBio Rises & More
@xconomy.com
5 years ago
Bio Roundup: NASH News, Merck Strikes, Digital Tokens & More
@xconomy.com
5 years ago
Bio Roundup: Alzheimer’s Fail, Drug Price Plan, Gene Therapies & More
@xconomy.com
5 years ago
Bio Roundup: Alzheimer’s Puzzle, ESMO Assessed, Drug Prices & More